News

Published on 27 Mar 2023 on Insider Monkey via Yahoo Finance

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2022 Earnings Call Transcript


Article preview image

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2022 Earnings Call Transcript March 23, 2023

Operator: Greetings and welcome to Relmada Therapeutics Fourth Quarter and Full Year 2022 Earnings Conference Call. As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Mr. Tim McCarthy. Thank you, you may begin.

Tim McCarthy: Thank you, operator, and thank you all for joining us this afternoon. With me on today's call are, Chief Executive Officer, Sergio Traversa; Chief Medical Officer, Dr. Cedric O'Gorman and Chief Financial Officer, Maged Shenouda. This afternoon, Relmada issued a news release providing a business update announcing financial results for the three and 12 months ended December 31, 2022. Please note that certain information discussed on the call today is covered under the safe harbor provisions of the Private Securities Litigation Reform Act. We caution listeners that during this call, Relmada's management team will be making forward-looking statements. Actual results could differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with the company's business.

NASDAQ.RLMD price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2023 Earnings Call Transcript

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2023 Earnings Call Transcript March 19, 2024 Relmada ...

Insider Monkey via Yahoo Finance 20 Mar 2024

Relmada Therapeutics Inc CEO Sergio Traversa Acquires 100,000 Shares

In a recent transaction on January 31, 2024, CEO Sergio Traversa of Relmada Therapeutics Inc (NAS...

GuruFocus.com via Yahoo Finance 29 Jan 2024

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q3 2023 Earnings Call Transcript

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q3 2023 Earnings Call Transcript November 9, 2023 Relmad...

Insider Monkey via Yahoo Finance 10 Nov 2023

Relmada Therapeutics Inc (RLMD) Reports Third Quarter 2023 Financial Results

Relmada Therapeutics Inc (NASDAQ:RLMD) advances Phase 3 clinical development for REL-1017 as an a...

GuruFocus.com via Yahoo Finance 8 Nov 2023

Following a 88% decline over last year, recent gains may please Relmada Therapeutics, Inc....

Key Insights Institutions' substantial holdings in Relmada Therapeutics implies that they have si...

Simply Wall St. via Yahoo Finance 16 Aug 2023

Relmada Therapeutics Insider Ups Holding By 62% During Year \

From what we can see, insiders were net buyers in Relmada Therapeutics, Inc.'s (NASDAQ:RLMD ) dur...

Simply Wall St. via Yahoo Finance 24 May 2023

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2022 Earnings Call Transcript

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2022 Earnings Call Transcript March 23, 2023 Operator...

Insider Monkey via Yahoo Finance 27 Mar 2023

Relmada Therapeutics, Inc. (NASDAQ:RLMD) is favoured by institutional owners who hold 52% of the...

If you want to know who really controls Relmada Therapeutics, Inc. (NASDAQ:RLMD), then you'll hav...

Simply Wall St. via Yahoo Finance 17 Feb 2023

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q3 2022 Earnings Call Transcript

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q3 2022 Earnings Call Transcript November 12, 2022 Opera...

Insider Monkey via Yahoo Finance 29 Dec 2022

Sergio Traversa Is The CEO & Director of Relmada Therapeutics, Inc. (NASDAQ:RLMD) And They Just...

Investors who take an interest in Relmada Therapeutics, Inc. (NASDAQ:RLMD) should definitely note...

Simply Wall St. via Yahoo Finance 15 Dec 2022